Life Science Leader Magazine

SEP 2014

The vision of Life Science Leader is to help facilitate connections and foster collaborations in pharma and med device development to get more life-saving and life-improving therapies to market in an efficient manner. Connect, Collaborate, Contribute

Issue link: https://lifescienceleadermag.epubxp.com/i/371566

Contents of this Issue

Navigation

Page 71 of 81

INDUSTRY LEADER insights LIFESCIENCELEADER.COM SEPTEMBER 2014 70 Peter Bigelow is president of xCell Strategic Consulting, a consulting f rm to the life sciences industry. In this position he provides management consulting services to a number of pharmaceutical clients. dards for product classes, consistent pen- alties for risky behavior, a drive for consis- tency across regions, and a consolidation of industry support organizations. We also need to see stronger integration of infor- mation technology in the supply chain, a seamless integration of data with suppliers, and investment in continuous manufactur- ing, electronic batch records, automated processes, and other IT advancements we have seen in other industries. Finally, there needs to be a greater focus on getting operational excellence right. Manufacturers must attack variabil- ity, waste, and inefficient processes with a vengeance. Managers must engage and motivate employees from top to bottom, while focusing on mindsets and behaviors. A focus on training will be essential, and when new ideas are adopted, they cannot be hypothetical. Managers must make sure the improvements are actually happening on the factory floor. ARE YOU MAKING PROGRESS? Once changes are made, how can you know progress is being made? There are several metrics that can be used to gauge progress. Critical drug shortages should be rare, and customer service metrics should indicate a 99% or greater shipment com- pletion rate. The pharmaceutical indus- try should be managing suppliers better than any other industry in the world. When regulatory actions have been all but eliminated, medicines are available to all at an appropriate cost, and when we have altered the risk/reward situa- tion for diverters and counterfeiters, we will know we are making progress. If changes are done correctly, drug manufacturers will not only secure their supply chains and reputations, but also will have the highest levels of compli- ance and customer service. The result will be safer medicines, fewer adverse events, and lower costs for pharma. L regulatory actions increasing exponentially. Business interruptions are now pervasive, with plant shutdowns resulting in drug shortages and higher manufacturing costs. TAKE A STRATEGIC APPROACH To improve supply chain performance and avoid costly and disruptive delays, compa- nies must take a strategic approach. This begins with setting goals that redefine performance. First and foremost, pharma must make 100% customer service levels their top priority. Pharma should strive for short cycle times, low inventory lev- els, and no products on the drug short- age list. Quality levels should be set that consistently beat expectations, including zero regulatory actions, processes with advanced warning systems in place, and value driven decisions being made at every level. Waste elimination must also be a top priority. Part of a strategic approach involves the preparation of a strategic plan. Several factors should be considered when pre- paring this plan. Counterfeiting and diver- sion are things the industry has to attack smartly and aggressively. To do this effec- tively, everyone in the supply chain has to be held accountable. Counterfeiters must be identified and prosecuted wherever in the world they happen to be. We must also devise creative solutions to fight coun- terfeiting quickly and effectively. These solutions must be supported by everyone, including regulators. Pharma companies must take needed steps to reinvent outsourcing. To assist in managing suppliers, firms should establish a set of GSPs (good supplier practices). Part of this is developing a set of metrics for suppliers and improving the way cus- tomers and suppliers communicate with each other. Cracking down on poor cGMP practices will require drug developers to support the audit services industry and the push for manufacturing uniformity. This should consist of an alignment of stan- The Supply Chain Of The Future: A Strategic View P E T E R B I G E L O W E volutionary theory teaches us it is neither the strongest nor the most intelligent of the spe- cies that survives. It is the one that is the most adaptable to change. Ingredient suppliers, manufacturers, quality standards and audits, and logis- tics are just a few areas where we can expect to see many changes. Adapting to these changes will be critical to everyone involved in the process and in ensuring that medicines are delivered to patients safely and effectively. The pharma supply chain has certainly undergone significant change in the last 40 years. In the 1970s and 1980s very lit- tle outsourcing was performed in phar- ma. Companies had separate domestic and international divisions, each with its own manufacturing. In the 1990s, API manufacturing became globalized, global quality standards were rolled out, and generic and biotech manufacturers emerged. In the first decade of the 21st century, dosage-form manufacturing went global, companies instituted operational improve- ment programs, external supply depart- ments were established, and outsourced products were managed more consistently. There was also greater scrutiny, with THE SUPPLY CHAIN OF THE FUTURE: A STRATEGIC VIEW By P. Bigelow

Articles in this issue

Links on this page

Archives of this issue

view archives of Life Science Leader Magazine - SEP 2014